Loading issue research
Gene-synthesis screening should be mandatory for every commercial provider, and AI cyber-offensive-capability evaluation should be a statutory duty inside AI-02's framework.
Verification Status
AI-researched, unverifiedLast Reviewed
Jul 6, 2026
Cited Sources
11
The specific delta between this position and the current mainstream approaches of both major parties.
This issue reveals the current administration's posture as non-monolithic rather than simply "deregulatory." The same administration that renamed the AI Safety Institute to the more competitiveness-focused CAISI, and paused the Biden-era nucleic-acid-synthesis- screening framework for revision, simultaneously used its own AI Action Plan to call for tightening bio-screening specifically because of AI-enabled biodesign risk. That's an internal tension, not a simple partisan story. Neither party has proposed the specific fix this issue calls for (mandatory, non-funding-conditional gene-synthesis screening for every commercial provider). This is a case where the Innovation Party's position is more stringent than either party's current legislative posture, not a synthesis point between two existing ones. On cyber-capability evaluation, the bipartisan-flavored CAISI/UK-AISI evaluation agreements with major labs suggest, if voluntary and non-statutory, cross- party appetite for testing to happen, just not yet backed by law from either side. Neither party has proposed a structured early-access program for critical-infrastructure hardening either; the closest existing analog, ISAC tiered information-sharing, is a decades-old, non-partisan model neither side treats as controversial, which is the strongest evidence this kind of program can be built without becoming a partisan fight over who the government picks as a winner.
Turn frustration into useful pressure.
If this position misses evidence or a lived consequence, challenge it. If it holds up, help test it locally and connect it to the issues around it.